 |
|
Obstructive Lung Disease and Low Lung Function in Adults in the United States
Data From the National Health and Nutrition Examination Survey, 1988-1994
David M. Mannino, MD;
Robert C. Gagnon, MS;
Thomas L. Petty, MD;
Eva Lydick, PhD
Arch Intern Med. 2000;160:1683-1689.
ABSTRACT
| |
Background Obstructive lung disease (OLD) is an important cause of morbidity and mortality in the US adult population. Potentially treatable mild cases of OLD often go undetected. This analysis determines the national estimates of reported OLD and low lung function in the US adult population.
Methods We examined data from the Third National Health and Nutrition Examination Survey (NHANES III), a multistage probability representative sample of the US population. A total of 20,050 US adults participated in NHANES III from 1988 to 1994. Our main outcome measures were low lung function (a condition determined to be present if the forced expiratory volume in 1 second–forced vital capacity ratio was less than 0.7 and the forced expiratory volume in 1 second was less than 80% of the predicted value), a physician diagnosis of OLD (chronic bronchitis, asthma, or emphysema), and respiratory symptoms.
Results Overall a mean (SE) of 6.8% (0.3%) of the population had low lung function, and 8.5% (0.3%) of the population reported OLD. Obstructive lung disease (age-adjusted to study population) was currently reported among 12.5% (0.7%) of current smokers, 9.4% (0.6%) of former smokers, 3.1% (1.1%) of pipe or cigar smokers, and 5.8% (0.4%) of never smokers. Surprisingly, 63.3% (0.2%) of the subjects with documented low lung function had no prior or current reported diagnosis of any OLD.
Conclusions This study demonstrates that OLD is present in a substantive number of US adults. In addition, many US adults have low lung function but no reported OLD diagnosis, which may indicate the presence of undiagnosed lung disease.
INTRODUCTION
OBSTRUCTIVE lung diseases (OLDs), which include chronic bronchitis, emphysema, and asthma, are the fourth most common cause of death in the United States and accounted for more than 109,000 deaths in 1997.1 Obstructive lung disease is the only major disease among the top 5 causes of death that is rising in prevalence and mortality.2 It is now estimated that nearly 16 million people in the United States have chronic bronchitis and emphysema, which is commonly referred to as chronic obstructive pulmonary disease (COPD).3 Costs of hospitalizations, physician visits, and consumption of health care resources for COPD were almost $15 billion in 1993.4 In addition, asthma may affect as many as 14.6 million people in the United States3, 5 with associated direct medical costs of $6.0 billion in 1993.6
Because of the increase in prevalence and mortality of OLD, and the medical costs associated with them, it is important to identify patients and to treat them before they reach the symptomatic and costly stages of disease. The Lung Health Study showed that when patients with mild to moderate OLD quit smoking, their lung function declined only slightly over the next 5 years.7 In contrast, similar patients who continued to smoke had rapid rates of decline in lung function. In addition, the Lung Health Study showed a high incidence of mortality related to lung cancer, heart attack, and stroke in subjects with only mild to moderate airflow obstruction.7
Because a high proportion of OLD has eluded diagnosis, it is impossible to know the true prevalence of these diseases in the United States today. To estimate the magnitude of OLD in the United States, we analyzed data from the Third National Health and Nutrition Examination Survey (NHANES III)8 in an effort to determine how much of the US population might have low levels of lung function, OLD, and respiratory symptoms.
SUBJECTS AND METHODS
STUDY POPULATION
The NHANES III was conducted from 1988 to 1994 by the National Center for Health Statistics of the Centers for Disease Control and Prevention, Atlanta, Ga.8 In this study a stratified multistage clustered probability design was used to select a representative sample of the US population, yielding results that can be extrapolated to the entire US population. Study participants completed extensive questionnaires in the household and a comprehensive physical examination, including pulmonary function testing, either in the household or at a specially equipped mobile examination center. A total of 81 sites were included in the final sample. The study was approved by the National Center for Health Statistics Institutional Review Board.
SUBJECTS
Our study sample was limited to adults aged 17 years and older who classified themselves as whites or blacks, had pulmonary function testing performed in either the home or the mobile examination center, and had complete data on their race, smoking status, height, and presence of respiratory symptoms. Of the 20,050 adult study participants, 543 were not of white or black race, 3355 did not have pulmonary function testing done, 8 were missing data on smoking status, race, or height, and 56 were missing data on 1 or more respiratory symptom. In addition, we excluded 4 women from the analysis who were current cigar or pipe smokers. After the exclusions, we had data from 16,084 subjects available for our main analysis.
VARIABLE DEFINITION
The race of the participants was classified as either white or black and was determined by self-report on the questionnaire. We defined subjects as being current smokers, former smokers, pipe or cigar smokers, or never smokers based on their responses to series of questions. One had to have smoked more than 100 cigarettes to qualify as a former or current smoker and could not be currently smoking cigarettes to qualify as a pipe or cigar smoker. Former smokers were asked how old they were when they last smoked cigarettes. Subjects were asked "Has a doctor ever told you that you asthma?" and similar questions about chronic bronchitis and emphysema. Subjects with a positive response to the question about asthma or chronic bronchitis were also asked "Do you still have asthma?" and "Do you still have chronic bronchitis?" We considered subjects who responded that they currently had asthma or bronchitis, or that they had ever had a diagnosis of emphysema, to have a current diagnosis of OLD. We considered subjects with a positive response to a previous diagnosis of either chronic bronchitis or asthma, but a negative response to current disease, to have a past diagnosis of OLD. We classified subjects as having a symptom if they gave a positive response to the following questions involving specific symptoms (cough, phlegm, wheezing, and dyspnea): "Do you usually cough on most days for 3 consecutive months or more during the year?" "Do you bring up phlegm on most days for 3 consecutive months or more during the year?" "Have you had wheezing or whistling in your chest at any time in the past 12 months?" and "Are you troubled by shortness of breath when hurrying on level ground or walking up a slight hill?" If a subject had a positive response to any of these 4 symptoms, we considered that subject to have a respiratory symptom.
For most analyses, we stratified subjects into 6 age strata; 17 to 24 years, 25 to 44 years, 45 to 64 years, 65 to 74 years, 75 to 84 years, and 85 years and older. For use in logistic regressions we classified subjects as having or not having cardiovascular disease (positive response to physician-diagnosed stroke, myocardial infarction, or congestive heart failure); obesity (body mass index [BMI] >28, calculated as the weight in kilograms divided by the square of the height in meters); inactivity (based on self report as being less active than peers); and low socioeconomic status (based on family income below poverty level).
PULMONARY FUNCTION DATA
Using either a dry rolling seal spirometer in the mobile examination center or a portable spirometer in the home examination, spirometry was conducted on the examinees. Procedures for testing were based on the 1987 American Thoracic Society recommendations.9 To obtain acceptable protocol curves, examinees performed 5 to 8 forced expirations. We used published prediction equations for forced expiratory volume in 1 second (FEV1) to calculate the predicted FEV1 for whites and blacks, stratified by sex.10 We then determined the value of the FEV1 (as a percentage of the predicted value) for each subject. We defined subjects with an FEV1–forced vital capacity (FVC) ratio of less than 0.70 and an FEV1 less than 80% of their predicted value as having low lung function, and further divided this group into subjects with an FEV1 of 50% or more and those with less than 50% of their predicted value, corresponding to people with stage 1 vs stage 2 or 3 OLD.11
ANALYSIS
We calculated all estimates using the sampling weight to represent adults aged 17 years and older in the United States. The purpose of these sampling weight calculations was to adjust for unequal probabilities of selection and to account for nonresponse. They were poststratified to the US population as estimated by the Bureau of the Census. For analyses, we used both SAS and SUDAAN, a program that adjusts for the complex sample design when calculating variance estimates.12 Most of our analyses stratified the data by race and sex, with further stratification by either smoking status or age. We also present data stratified by reported lung disease and level of lung function. In these strata and substrata, we determined the estimated national population, the mean FEV1 as percent predicted, the mean FEV1-FVC ratio, and the number and age-adjusted percentage of the population with low lung function. We used the 6 age classes noted above and the overall age distribution of the study participants to age-adjust our results. In addition, we determined the number and age-adjusted percentage of the population with past or current OLD and the age-adjusted percentage of the population with cough, phlegm, wheezing, dyspnea, or any respiratory symptom. We also determined the age-adjusted percentage of the population stratified by race, sex, and smoking status with low lung function but with no current diagnosis of any OLD. Finally, we modeled, using logistic regression, factors predicting subjects who were unable to perform pulmonary function testing, subjects with low lung function, and subjects with low lung function yet no reported OLD.
RESULTS
Our final data set contained 16,084 subjects representing an estimated 169.3 million adults in the United States. Relative SEs for the data presented are less than 10%, except for data on pipe and cigar smokers, where the RSEs are less than 35%. Among the population, an estimated 14.3 million (8.5%) had current OLD, and another 7.3 million (4.3%) had OLD in the past, but not currently (Table 1). The proportion of the population with past or current OLD varied by sex, race, and smoking status, with women reporting more disease than men, whites reporting more disease than blacks, and current or former smokers reporting more disease than never smokers (Table 1). Obstructive lung disease was present among 12.5% of current smokers, 9.4% of former smokers, 3.1% of pipe or cigar smokers, and 5.8% of never smokers (all age-adjusted to study population). Former smokers were, on average, older than never and current smokers (Table 1). Mean level of lung function, either as the FEV1-FVC ratio or FEV1 percent predicted, was always lower among current smokers, former smokers, and pipe or cigar smokers, compared with never smokers (Table 1). Among whites, the reported COPD component of OLD generally increased with age, while among blacks this trend was less apparent (Figure 1).
|
|
|
|
Table 1. Characteristics of Participants and Estimated National Population, Stratified by Race, Sex, and Smoking Status*
|
|
|
|
|
|
|
Figure 1. The age-specific percentage of people (numbers are age ranges in years), stratified by race and sex, with current chronic obstructive pulmonary disease (COPD) (chronic bronchitis and pnuemonia) and asthma, current COPD, current asthma, and past chronic bronchitis or asthma. From the Third National Health and Nutrition Examination Survey, 1988-94.8
|
|
|
Subjects frequently reported more than 1 OLD. For example, 25.0% of subjects with current bronchitis reported that they had current asthma, and 34.3% of subjects with current asthma reported that they had current chronic bronchitis. Similarly, 19.4% of the subjects with emphysema reported that they had current asthma, and 25.0% of the subjects with emphysema reported that they had current chronic bronchitis. Among subjects who reported having at some point been diagnosed with asthma, 63.7% reported current asthma, and 58.3% of subjects who reported having been at some point diagnosed with chronic bronchitis also reported a current diagnosis.
Pulmonary function testing was not obtained on 3355 of the original 20,050 subjects. The significant predictors of not having testing done were the presence of cardiovascular disease (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.2-1.7) and age (OR, 1.9; 95% CI, 1.4-2.5 for those aged 65-74 years; OR, 2.9; 95% CI, 2.3-3.8 for those aged 75-84 years; and OR, 5.3; 95% CI, 3.8-7.3 for those aged 85 years and older, compared with those aged 17-24 years). Overall, 6.8% of the population, or an estimated 11.5 million people had low lung function (Table 2). An additional 7.2% of the population had an FEV1-FVC ratio of less than 0.7 but an FEV1 greater than 80% of the predicted value. Significant predictors of low lung function included current smoking (OR, 4.3; 95% CI, 3.2-5.7), former smoking (OR, 2.0; 95% CI, 1.5-2.5), pipe or cigar smoking (OR, 2.7; 95% CI, 1.4-5.0), current OLD (OR, 5.4; 95% CI, 4.1-7.0), prior OLD (OR, 1.8; 95% CI, 1.0-3.0), and age (ORs increased from 2.1 for those aged 25 to 44 years to 21.0 for those aged 85 years and older, compared with 17- to 24-year-olds, all CIs significant). Moderate to severe lung obstruction (FEV1 less than 50% of the predicted value and an FEV1-FVC ratio of less than 0.7) was more common among current and former smokers and among people aged 45 years and older (Figure 2 and Figure 3). Overall, 1.5% of the population, or an estimated 2.6 million people, had an FEV1 of less than 50% of the predicted value, including an estimated 900,000 people with an FEV1 of less than 35% of the predicted value. Lower levels of lung function were associated with higher levels of reported symptoms (Table 3).
|
|
|
|
Table 2. Characteristics of Participants With Low Lung Function, Stratified by Race, Sex, and Smoking Status*
|
|
|
|
|
|
|
Figure 2. The age-specific percentage of people (numbers are age ranges in years), stratified by race and sex, with a forced expiratory volume in 1 second (FEV1)–forced vital capacity (FVC) ratio of less than 0.70 and an FEV1 50% to 80% or less than 50% of the expected value. From the Third National Health and Nutrition Examination Survey, 1988-94.8
|
|
|
|
|
|
|
Figure 3. The age-adjusted percentage of people, stratified by race, sex, and smoking status (current smokers [CS], former smokers [FS], pipe or cigar smokers [PCS] and never smokers [NS]), with a forced expiratory volume in 1 second (FEV1)–forced vital capacity (FVC) ratio of less than 0.70 and an FEV1 50% to 80% or less than 50% of the expected value. From the Third National Health and Nutrition Examination Survey, 1988-94.8
|
|
|
|
|
|
|
Table 3. Characteristics of Participants With Low Lung Function, Stratified by Reported Lung Disease and Level of Lung Function*
|
|
|
Current and former smokers reported respiratory symptoms more frequently than never smokers (Table 2). Reporting of symptoms varied across disease strata (Table 3). Among subjects with low lung function, 66.1% reported at least 1 respiratory symptom (Table 3), compared with 34.4% of subjects with normal pulmonary function. There was a great deal of overlap between subjects reporting respiratory symptoms, those with low lung function, and those with current or prior OLD (Figure 4, Table 3).
|
|
|
|
Figure 4. A proportional Venn diagram of the prevalence of low lung function (forced expiratory volume in one second [FEV1]–forced vital capacity [FVC] ratio of less than 0.70 and an FEV1 less than 80% of the expected value), current or past diagnosis of obstructive lung disease, and the presence of 1 or more respiratory symptoms. From the Third National Health and Nutrition Examination Survey, 1988-94.8
|
|
|
Overall, 63.3% of the population with low lung function did not have a current diagnosis of OLD. Even among subjects with moderate to severe pulmonary impairment, as indicated by an FEV1 of less than 50% of the predicted value, 44.0% did not have a current diagnosis of OLD. Across sex, race, and smoking categories this proportion ranged from 40% to 88% (Figure 5). People with a past diagnosis of obstructive lung disease accounted for a small proportion of this group of subjects not currently diagnosed (Figure 5). The only significant predictors of low lung function without a current diagnosis of OLD were current smoking (OR, 1.6; 95% CI, 1.0-2.5), inactivity (OR, 0.6; 95% CI, 0.4-0.9), and cardiovascular disease (OR, 0.5; 95% CI, 0.3-0.7).
|
|
|
|
Figure 5. The age-adjusted percentage of people with a forced expiratory volume in 1 second (FEV1)–forced vital capacity (FVC) ratio of less than 0.70 and an less than 80% of the expected value and either no diagnosis or a past diagnosis of obstructive lung disease, stratified by race, sex, and smoking status (current smokers [CS], former smokers [FS], pipe or cigar smokers [PCS], and never smokers [NS]). From the Third National Health and Nutrition Examination Survey, 1988-94.8
|
|
|
COMMENT
These data show that low lung function and OLD occur commonly in a nationally representative sample of the US population. Low lung function is found in more than 10% of the population over age 45 years, but is not associated with reported current OLD 63.3% of the time. This finding is important, because when these patients can be identified in early and less symptomatic stages of disease, interventions can be expected to alter the course and prognosis of disease.7, 13-14 Clearly, smoking cessation is the most important feature in management and is apt to be beneficial when it is accomplished at an early age with only mild evidence of airflow obstruction. While the finding of low lung function does not by itself diagnose OLD, its presence should alert clinicians to the possibility of OLD being present, resulting in subsequent evaluations and interventions.
These results confirm the findings of many previous studies, which show associations between cigarette smoking and pulmonary effects, including low lung function and respiratory symptoms.13, 15-16 A somewhat surprising finding, though, was that cigar or pipe smokers had a higher prevalence of low lung function than never smokers, along with more reported respiratory symptoms, a finding that runs counter to studies finding fewer smoking-related health effects in pipe or cigar smokers.17 Our study suggests that pipe and cigar smokers are getting enough doses of smoke to cause lung damage, but our findings may also reflect, in part, former cigarette smoking (in our study, 69.3% of pipe and cigar smokers were former cigarette smokers).18 In addition, our finding of decreased lung function in pipe and cigar smokers demands intervening in this group.
The results of our analysis also confirmed previously known associations between aging and increased airway obstruction.19 The prevalence of low lung function increased with increasing age (Figure 2) except in the oldest group, which may be related to either differential mortality or inability to do pulmonary function testing. While it is certainly known that the individuals with low lung function die young,13, 20-21 our data also suggest that people over age 45 years may have significantly decreased lung function that remains undiagnosed (Figure 2 and Figure 5). The patterns we found of reported OLD also were consistent with reports of COPD increasing with age3 (Figure 1). The racial differences we observed, of generally lower levels of reported COPD in blacks compared with whites, is consistent with other observations.3
There have been numerous, but much smaller regional prevalence studies done in the United States, most notably in Berlin, NH22; Tecumseh, Mich23; and Glenwood Springs, Colo.24 These studies used different degrees of airflow obstruction and had different definitions of the diseases characterized by airflow obstruction. In Berlin, NH, the prevalence of all chronic nonspecific respiratory diseases ranged from 15.4% to 39.1% among men and from 15.2% to 19.8% among women, and low levels of lung function were found among 3.1% to 21.7% of men and 6.7% to 13.9% of women.22 In Tecumseh, Mich, about 14% of adult men and 8% of adult women had chronic bronchitis, obstructive airway disease, or both.23 In Glenwood Springs, Colo, about 13% of adult men and 10% of adult women had chronic bronchitis and 13% and 4%, respectively, had low lung function.24 The above-noted findings can be contrasted with our own findings of 8.5% of adults reporting current OLD and 6.8% having low lung function.
Our data also showed a large degree of overlap between asthma and COPD. Subjects with both diseases had lower lung function and more respiratory symptoms than subjects with just one or the other disease (Table 3). Asthma is a potentially reversible disease when diagnosed and treated early in its course with bronchoactive and anti-inflammatory medications.25-26 By contrast, COPD tends to be a progressive disease, with relentless decline in lung function and resultant morbidity and mortality beginning in the fifth or sixth decade of life.25 Preventing or forestalling this burden of disease may be possible through aggressive smoking cessation and, perhaps, medications that may improve baseline lung function. The search for other drugs to modulate the inflammatory processes incident to the pathogenesis of COPD is also ongoing.27-34
This survey is subject to several limitations that affect the interpretation of these results. The entire medical history, including the previous and current diagnoses, the respiratory symptoms, and the smoking histories, were entirely self-reported. It is possible that subjects may have underreported or overreported in any of these categories. For instance, we found that only 33.9% and 25.6% of subjects with COPD reported cough and phlegm, respectively. While the criteria for a positive response to these questions were stringent, this may indicate that either symptom or disease reporting was inaccurate. Another limitation was that current smokers who either smoked irregularly or had just stopped smoking could be misclassified as former smokers. In our analyses, however, many of our findings were consistent with known relationships between respiratory disease, respiratory symptoms, and lung function, suggesting that any misreporting bias potentially present did not have a large effect on the results.
Another potential bias of this study design is that not everyone completed pulmonary function testing. It is possible that subjects unable to do pulmonary function testing were also more likely to have low levels of lung function, thus resulting in an underestimate in the burden of the prevalence of low lung function in the United States. Selection was limited to a noninstitutionalized, nonmilitary population, so it was not truly randomized to a general population. Only patients who were ambulatory and able to participate were studied, which might have created a selection bias.
Pulmonary function testing may provide an interventional opportunity in the United States. Since early intervention may alter the course and prognosis of OLD, it is important that all clinicians who encounter smokers and any patient with respiratory symptoms, particularly those over age 45 years, be able to make an accurate diagnosis. Previous studies have shown, though, that symptoms alone are not adequate to diagnose COPD,35-36 and that spirometry may need to be more widely used to detect early disease.4
The National Lung Health Education Program is a new health care initiative aimed at involving primary care physicians in the early identification and treatment of obstructive lung disease.4 The National Lung Health Education Program is promoting the widespread use of simple office spirometry to measure the FEV1, FVC, and FEV1-FVC ratio. The present study demonstrates that a significant proportion of the US population older than 45 years has low lung function, which may represent unrecognized and potentially treatable OLD. Spirometry remains the most efficient means of identifying and treating this population.
AUTHOR INFORMATION
Accepted for publication, November 17, 1999.
Reprints: David M. Mannino, MD, National Center for Environmental Health, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS E-17, Atlanta, GA 30341-3724 (e-mail: dmm6{at}cdc.gov).
From the Air Pollution and Respiratory Health Branch, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Ga (Dr Mannino); SmithKline Beecham Pharmaceuticals, Collegeville, Pa (Drs Gagnon and Lydick); and the University of Colorado Health Sciences Center, Denver, Colo (Dr Petty).
REFERENCES
| |
1. Hoyert DL, Kochan KD, Murphy SL. Death: Final Data for 1997 National Vital Statistics Reports 1999. Hyattsville, Md: National Center for Health Statistics; 1999. US Dept of Health and Human Services publication PHS 99-1120.
2. Centers for Disease Control and Prevention. Mortality patterns: preliminary data, United States, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:941-944.
PUBMED
3. Adams PF, Hendershoot GE, Marano MA. Currente Estimates From the National Health Interview Survey, 1996. Hyattsville, Md: National Center for Health Statistics; 1999. US Dept of Health and Human Services publication PHS 99-1528.
4. The National Lung Health Education Program (NLHEP). Strategies in preserving lung health and preventing COPD and associated diseases. Chest. 1998;113(suppl):123S-163S.
5. Mannino DM, Homa DM, Pertowski CA, et al. Surveillance for asthma: United States, 1960-1995. Mor Mortal Wkly Rep CDC Surveill Summ. 1998;47:1-27.
6. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med. 1992;326:862-866.
ABSTRACT
7. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994;272:1497-1505.
FREE FULL TEXT
8. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94; 1994. US Dept of Health and Human Services publication PHS 94-1308.
9. American Thoracic Society. Standardization of spirometry—1987 update: statement of the American Thoracic Society. Am Rev Respir Dis. 1987;136:1285-1298.
ISI
| PUBMED
10. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S.population. Am J Respir Crit Care Med. 1999;159:179-187.
FREE FULL TEXT
11. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152(suppl):S77-S121.
12. Shah BV, Barnwell BG, Bieler GS. SUDAAN User's Manual, Release 7.0. Research Triangle Park, NC: Research Triangle Institute; 1996.
13. Peto R, Speizer FE, Cochrane AL, et al. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease: results from 20 years of prospective observation. Am Rev Respir Dis. 1983;128:491-500.
ISI
| PUBMED
14. Higgins M. Epidemiology of COPD: state of the art. Chest. 1984;85(suppl):3S-8S.
15. Burrows B, Lebowitz MD, Camilli AE, Knudson RJ. Longitudinal changes in forced expiratory volume in one second in adults: methodologic considerations and findings in healthy nonsmokers. Am Rev Respir Dis. 1986;133:974-980.
ISI
| PUBMED
16. Rennard SI. COPD: overview of definitions, epidemiology, and factors influencing its development. Chest. 1998;113(suppl):235S-241S.
17. Wald NJ, Watt HC. Prospective study of effect of switching from cigarettes to pipes or cigars on mortality from three smoking-related diseases. BMJ. 1997;314:1860-1863.
FREE FULL TEXT
18. Nelson DE, Davis RM, Chrismon JH, Giovino GA. Pipe smoking in the United States, 1965-1991: prevalence and attributable mortality. Prev Med. 1996;25:91-99.
FULL TEXT
|
ISI
| PUBMED
19. Wise RA. Changing smoking patterns and mortality from chronic obstructive pulmonary disease. Prev Med. 1997;26:418-421.
FULL TEXT
|
ISI
| PUBMED
20. Weiss ST, Segal MR, Sparrow D, Wager C. Relation of FEV1 and peripheral blood leukocyte count to total mortality: the normative aging study. Am J Epidemiol. 1995;142:493-498.
FREE FULL TEXT
21. Petty TL, Pierson DJ, Dick NP, Hudson LD, Walker SH. Follow-up evaluation of a prevalence study for chronic bronchitis and chronic airway obstruction. Am Rev Respir Dis. 1976;114:881-890.
ISI
| PUBMED
22. Ferris BG Jr, Anderson DO. The prevalence of chronic respiratory disease in a New Hampshire town. Am Rev Respir Dis. 1962;86:165-177.
23. Higgins MW, Keller JB, Landis JR, et al. Risk of chronic obstructive pulmonary disease: collaborative assessment of the validity of the Tecumseh index of risk. Am Rev Respir Dis. 1984;130:380-385.
ISI
| PUBMED
24. Mueller RE, Keble DL, Plummer J, Walker SH. The prevalence of chronic bronchitis, chronic airway obstruction, and respiratory symptoms in a Colorado city. Am Rev Respir Dis. 1971;103:209-228.
ISI
| PUBMED
25. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med. 1987;317:1309-1314.
ABSTRACT
26. Burrows B. The course and prognosis of different types of chronic airflow limitation in a general population sample from Arizona: comparison with the Chicago "COPD" series. Am Rev Respir Dis. 1989;140(suppl):S92-S94.
27. Anthonisen NR. OM-8BV for COPD. Am J Respir Crit Care Med. 1997;156:1713-1714.
FREE FULL TEXT
28. Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;156:1719-1724.
FREE FULL TEXT
29. Tomee JF, Koeter GH, Hiemstra PS, Kauffman HF. Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option? Thorax. 1998;53:114-116.
ABSTRACT
30. van Schayck CP, van Grunsven PM, Dekhuijzen PN. Do patients with COPD benefit from treatment with inhaled corticosteroids? Eur Respir J. 1996;9:1969-1972.
FULL TEXT
|
ISI
| PUBMED
31. Dompeling E, van Schayck CP, van Grunsven PM, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: a 4-year prospective study. Ann Intern Med. 1993;118:770-778.
FREE FULL TEXT
32. Kerstjens HA, Brand PL, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med. 1992;327:1413-1419.
ABSTRACT
33. Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax. 1998;53:583-585.
FREE FULL TEXT
34. Shahar E, Folsom AR, Melnick SL, et al. Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary disease. N Engl J Med. 1994;331:228-233.
FREE FULL TEXT
35. Mannino DM, Etzel RA, Flanders WD. Do the medical history and physical examination predict low lung function? Arch Intern Med. 1993;153:1892-1897.
FREE FULL TEXT
36. Badgett RG, Tanaka DJ, Hunt DK, et al. Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? Am J Med. 1993;94:188-196.
FULL TEXT
|
ISI
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Prevalence, Incidence, and Lifetime Risk for the Development of COPD in the Elderly: The Rotterdam Study
van Durme et al.
Chest 2009;135:368-377.
ABSTRACT
| FULL TEXT
Spirometry Utilization After Hospitalization for Patients With Chronic Obstructive Pulmonary Disease Exacerbations
Volkova et al.
American Journal of Medical Quality 2009;24:61-66.
ABSTRACT
COPD Prevalence in Southeastern Kentucky: The Burden of Lung Disease Study
Methvin et al.
Chest 2009;135:102-107.
ABSTRACT
| FULL TEXT
Natural Histories of Chronic Obstructive Pulmonary Disease
Rennard and Vestbo
Proc Am Thorac Soc 2008;5:878-883.
ABSTRACT
| FULL TEXT
Effect of Smoking on Spirometry of African American and White Subjects
Berry et al.
Chest 2008;134:1231-1236.
ABSTRACT
| FULL TEXT
Chronic cough - occupational considerations
Barber and Fishwick
Chronic Respiratory Disease 2008;5:211-221.
ABSTRACT
Will Recommendations against Spirometry Make Chronic Obstructive Pulmonary Disease Harder to Treat?
Petty and Mannino
ANN INTERN MED 2008;149:512-513.
FULL TEXT
Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD
Bridevaux et al.
Thorax 2008;63:768-774.
ABSTRACT
| FULL TEXT
Coexisting Asthma and COPD: Confused Clinicians or Poor Prognosticator?
Mannino
Chest 2008;134:1-2.
FULL TEXT
Impact of chronic airflow obstruction in a working population
Roche et al.
Eur Respir J 2008;31:1227-1233.
ABSTRACT
| FULL TEXT
A mixed methods study to compare models of spirometry delivery in primary care for patients at risk of COPD
Walters et al.
Thorax 2008;63:408-414.
ABSTRACT
| FULL TEXT
Update in Chronic Obstructive Pulmonary Disease 2007
MacNee
Am. J. Respir. Crit. Care Med. 2008;177:820-829.
FULL TEXT
Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force
ANN INTERN MED 2008;148:529-534.
ABSTRACT
| FULL TEXT
Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: Summary of the Evidence for the U.S. Preventive Services Task Force
Lin et al.
ANN INTERN MED 2008;148:535-543.
ABSTRACT
| FULL TEXT
Prevalence of COPD in Five Colombian Cities Situated at Low, Medium, and High Altitude (PREPOCOL Study)
Caballero et al.
Chest 2008;133:343-349.
ABSTRACT
| FULL TEXT
The impact of the 2004 NICE guideline and 2003 General Medical Services contract on COPD in primary care in the UK
Smith et al.
QJM 2008;101:145-153.
ABSTRACT
| FULL TEXT
Authors' reply
Mannino et al.
Thorax 2007;62:1108-1109.
FULL TEXT
Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians
Qaseem et al.
ANN INTERN MED 2007;147:633-638.
ABSTRACT
| FULL TEXT
The Epidemiology and Economics of Chronic Obstructive Pulmonary Disease
Mannino and Braman
Proc Am Thorac Soc 2007;4:502-506.
ABSTRACT
| FULL TEXT
Differentiating COPD From Asthma in Clinical Practice
Chang and Mosenifar
J Intensive Care Med 2007;22:300-309.
ABSTRACT
Defining chronic obstructive pulmonary disease... and the elephant in the room
Mannino
Eur Respir J 2007;30:189-190.
FULL TEXT
COPD prevalence in a random population survey: a matter of definition
Shirtcliffe et al.
Eur Respir J 2007;30:232-239.
ABSTRACT
| FULL TEXT
Palliative care in chronic obstructive pulmonary disease: a review for clinicians
Seamark et al.
JRSM 2007;100:225-233.
ABSTRACT
| FULL TEXT
Pulmonary Rehabilitation Executive Summary: Joint American College of Chest Physicians/American Association of Cardiovascular and Pulmonary Rehabilitation Evidence-Based Clinical Practice Guidelines
Ries et al.
Chest 2007;131:1S-3S.
FULL TEXT
Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines
Ries et al.
Chest 2007;131:4S-42S.
ABSTRACT
| FULL TEXT
Prevalence and Risks of Chronic Airway Obstruction: A Population Cohort Study in Taiwan
Wang et al.
Chest 2007;131:705-710.
ABSTRACT
| FULL TEXT
COPD Prevalence in Salzburg, Austria: Results From the Burden of Obstructive Lung Disease (BOLD) Study
Schirnhofer et al.
Chest 2007;131:29-36.
ABSTRACT
| FULL TEXT
Diagnostic Labeling of COPD in Five Latin American Cities
Talamo et al.
Chest 2007;131:60-67.
ABSTRACT
| FULL TEXT
The Quality of Obstructive Lung Disease Care for Adults in the United States as Measured by Adherence to Recommended Processes
Mularski et al.
Chest 2006;130:1844-1850.
ABSTRACT
| FULL TEXT
Underdiagnosed chronic obstructive pulmonary disease in England: new country, same story.
Mannino
Thorax 2006;61:1032-1034.
FULL TEXT
Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample
Shahab et al.
Thorax 2006;61:1043-1047.
ABSTRACT
| FULL TEXT
Increased COPD Among HIV-Positive Compared to HIV-Negative Veterans.
Crothers et al.
Chest 2006;130:1326-1333.
ABSTRACT
| FULL TEXT
A simple score for assessing stable chronic obstructive pulmonary disease
Esteban et al.
QJM 2006;99:751-759.
ABSTRACT
| FULL TEXT
Potential misclassification of causes of death from COPD
Jensen et al.
Eur Respir J 2006;28:781-785.
ABSTRACT
| FULL TEXT
Thirty-Year Cumulative Incidence of Chronic Bronchitis and COPD in Relation to 30-Year Pulmonary Function and 40-Year Mortality: A Follow-up in Middle-Aged Rural Men.
Pelkonen et al.
Chest 2006;130:1129-1137.
ABSTRACT
| FULL TEXT
Chronic Obstructive Pulmonary Disease: The Disease and Its Burden to Society
Halpin and Miravitlles
Proc Am Thorac Soc 2006;3:619-623.
ABSTRACT
| FULL TEXT
Global burden of COPD: systematic review and meta-analysis
Halbert et al.
Eur Respir J 2006;28:523-532.
ABSTRACT
| FULL TEXT
Women and Chronic Obstructive Pulmonary Disease: Does Sex Influence Survival?
Mannino
Am. J. Respir. Crit. Care Med. 2006;174:488-489.
FULL TEXT
GOLD Stage 0 COPD: Is it Real? Does it Matter?
Mannino
Chest 2006;130:309-310.
FULL TEXT
Asthma and chronic obstructive pulmonary disease exhibit common origins in any country!
Kraft
Am. J. Respir. Crit. Care Med. 2006;174:238-240.
FULL TEXT
Patient and Surgical Factors Influencing Air Leak After Lung Volume Reduction Surgery: Lessons Learned From the National Emphysema Treatment Trial
DeCamp et al.
Ann. Thorac. Surg. 2006;82:197-207.
ABSTRACT
| FULL TEXT
Advanced emphysema in african-american and white patients: do differences exist?
Chatila et al.
Chest 2006;130:108-118.
ABSTRACT
| FULL TEXT
Vapor, Dust, and Smoke Exposure in Relation to Adult-Onset Asthma and Chronic Respiratory Symptoms: The Singapore Chinese Health Study
LeVan et al.
Am J Epidemiol 2006;163:1118-1128.
ABSTRACT
| FULL TEXT
Spirometry Use in Clinical Practice Following Diagnosis of COPD
Lee et al.
Chest 2006;129:1509-1515.
ABSTRACT
| FULL TEXT
Chronic Obstructive Pulmonary Disease: Linking Outcomes and Pathobiology of Disease Modification
Rennard
Proc Am Thorac Soc 2006;3:276-280.
ABSTRACT
| FULL TEXT
Increasing COPD awareness.
Zielinski et al.
Eur Respir J 2006;27:833-852.
FULL TEXT
Seven-Year Cumulative Incidence of COPD in an Age-Stratified General Population Sample.
Lindberg et al.
Chest 2006;129:879-885.
ABSTRACT
| FULL TEXT
Chronic obstructive pulmonary disease: current burden and future projections
Lopez et al.
Eur Respir J 2006;27:397-412.
FULL TEXT
Prognostic value of chronic obstructive pulmonary disease in coronary artery bypass grafting
Fuster et al.
Eur. J. Cardiothorac. Surg. 2006;29:202-209.
ABSTRACT
| FULL TEXT
Chronic Cough Due to Chronic Bronchitis: ACCP Evidence-Based Clinical Practice Guidelines
Braman
Chest 2006;129:104S-115S.
ABSTRACT
| FULL TEXT
"Haeso Cheonsik" and Chronic Obstructive Pulmonary Disease in Korea
Mannino
Am. J. Respir. Crit. Care Med. 2005;172:795-796.
FULL TEXT
Prevalence of Chronic Obstructive Pulmonary Disease in Korea: A Population-based Spirometry Survey
Kim et al.
Am. J. Respir. Crit. Care Med. 2005;172:842-847.
ABSTRACT
| FULL TEXT
Prevalence of undetected persistent airflow obstruction in male smokers 40-65 years old
Geijer et al.
Fam Pract 2005;22:485-489.
ABSTRACT
| FULL TEXT
Invited Commentary: Considering Bias in the Assessment of Respiratory Symptoms among Residents of Lower Manhattan following the Events of September 11, 2001
Vlahov and Galea
Am J Epidemiol 2005;162:508-510.
FULL TEXT
Detecting Airflow Obstruction in Smoking Cessation Trials: A Rationale for Routine Spirometry
Bohadana et al.
Chest 2005;128:1252-1257.
ABSTRACT
| FULL TEXT
Chronic obstructive pulmonary disease in 2025: where are we headed?
Mannino
Eur Respir J 2005;26:189-189.
FULL TEXT
Asthma and incident cardiovascular disease: the Atherosclerosis Risk in Communities Study
Schanen et al.
Thorax 2005;60:633-638.
ABSTRACT
| FULL TEXT
Ten-Year Cumulative Incidence of COPD and Risk Factors for Incident Disease in a Symptomatic Cohort
Lindberg et al.
Chest 2005;127:1544-1552.
ABSTRACT
| FULL TEXT
Clinical Approach to Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Disease
Rennard
Proc Am Thorac Soc 2005;2:94-100.
ABSTRACT
| FULL TEXT
Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004
Decramer et al.
Thorax 2005;60:343-349.
ABSTRACT
| FULL TEXT
Prevalence of Chronic Obstructive Pulmonary Disease Among Those With Serious Mental Illness
Himelhoch et al.
Am. J. Psychiatry 2004;161:2317-2319.
ABSTRACT
| FULL TEXT
The Proportional Venn Diagram of Obstructive Lung Disease in the Italian General Population
Viegi et al.
Chest 2004;126:1093-1101.
ABSTRACT
| FULL TEXT
The association between occupational factors and adverse health outcomes in chronic obstructive pulmonary disease
Blanc et al.
Occup. Environ. Med. 2004;61:661-667.
ABSTRACT
| FULL TEXT
Similarities and Differences in Asthma and COPD: The Dutch Hypothesis
Bleecker
Chest 2004;126:93S-95S.
FULL TEXT
Physiologic Similarities and Differences Between COPD and Asthma
Sciurba
Chest 2004;126:117S-124S.
ABSTRACT
| FULL TEXT
Obstructive Lung Disease Among the Urban Homeless
Snyder and Eisner
Chest 2004;125:1719-1725.
ABSTRACT
| FULL TEXT
Office Spirometry Significantly Improves Early Detection of COPD in General Practice: The DIDASCO Study
Buffels et al.
Chest 2004;125:1394-1399.
ABSTRACT
| FULL TEXT
Prevalence of COPD in Greece
Tzanakis et al.
Chest 2004;125:892-900.
ABSTRACT
| FULL TEXT
Urinary cadmium levels predict lower lung function in current and former smokers: data from the Third National Health and Nutrition Examination Survey
Mannino et al.
Thorax 2004;59:194-198.
ABSTRACT
| FULL TEXT
Prospective Study of Postmenopausal Hormone Use and Newly Diagnosed Asthma and Chronic Obstructive Pulmonary Disease
Barr et al.
Arch Intern Med 2004;164:379-386.
ABSTRACT
| FULL TEXT
Integrated Health System for Chronic Disease Management: Lessons Learned From France
Stuart and Weinrich
Chest 2004;125:695-703.
ABSTRACT
| FULL TEXT
Smoking Patterns in African Americans and Whites With Advanced COPD
Chatila et al.
Chest 2004;125:15-21.
ABSTRACT
| FULL TEXT
Airway Obstruction Is Common but Unsuspected in Patients Admitted to a General Medicine Service
Zaas et al.
Chest 2004;125:106-111.
ABSTRACT
| FULL TEXT
The occupational burden of chronic obstructive pulmonary disease
Trupin et al.
Eur Respir J 2003;22:462-469.
ABSTRACT
| FULL TEXT
The pharmacoepidemiology of COPD: Recent advances and methodological discussion
Eur Respir J 2003;22:1s-44s.
FULL TEXT
Population impact of different definitions of airway obstruction
Celli et al.
Eur Respir J 2003;22:268-273.
ABSTRACT
| FULL TEXT
Animal production and wheeze in the Agricultural Health Study: interactions with atopy, asthma, and smoking
Hoppin et al.
Occup. Environ. Med. 2003;60:e3-3.
ABSTRACT
| FULL TEXT
The Proportional Venn Diagram of Obstructive Lung Disease: Two Approximations From the United States and the United Kingdom
Soriano et al.
Chest 2003;124:474-481.
ABSTRACT
| FULL TEXT
Impaired lung function and serum leptin in men and women with normal body weight: a population based study
Sin and Man
Thorax 2003;58:695-698.
ABSTRACT
| FULL TEXT
Low Lung Function and Incident Lung Cancer in the United States: Data From the First National Health and Nutrition Examination Survey Follow-up
Mannino et al.
Arch Intern Med 2003;163:1475-1480.
ABSTRACT
| FULL TEXT
Rescue! Therapy and the paradox of the Barcalounger
Rennard and Calverley
Eur Respir J 2003;21:916-917.
FULL TEXT
Prevalence and Correlates of Airway Obstruction in a Community-Based Sample of Adults
Shin et al.
Chest 2003;123:1924-1931.
ABSTRACT
| FULL TEXT
COPD: problems in diagnosis and measurement
Weiss et al.
Eur Respir J 2003;21:4S-12s.
ABSTRACT
| FULL TEXT
Current Practice in Pulmonary Function Testing
Evans and Scanlon
Mayo Clin Proc. 2003;78:758-763.
ABSTRACT
Chronic obstructive pulmonary disease and dyspnea: A Pandora's box of comorbid symptoms?
Cox et al.
AM J HOSP PALLIAT CARE 2003;20:179-181.
Interpreting COPD Prevalence Estimates: What Is the True Burden of Disease?
Halbert et al.
Chest 2003;123:1684-1692.
ABSTRACT
| FULL TEXT
Does Your Child Have Asthma?: Parent Reports and Medication Use for Pediatric Asthma
Roberts
Arch Pediatr Adolesc Med 2003;157:449-455.
ABSTRACT
| FULL TEXT
Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly
Lundback et al.
Eur Respir J 2003;21:3S-9s.
ABSTRACT
| FULL TEXT
Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study
Mannino et al.
Thorax 2003;58:388-393.
ABSTRACT
| FULL TEXT
Clinical Research in Chronic Obstructive Pulmonary Disease: Needs and Opportunities
Croxton et al.
Am. J. Respir. Crit. Care Med. 2003;167:1142-1149.
ABSTRACT
| FULL TEXT
Survival in COPD patients after regular use of fluticasone propionate and salmeterol
Marchand
Eur Respir J 2003;21:559-560.
FULL TEXT
COPD Screening in High-Risk Groups
Cerveri et al.
Chest 2003;123:959-960.
FULL TEXT
American Thoracic Society Statement: Occupational Contribution to the Burden of Airway Disease
Am. J. Respir. Crit. Care Med. 2003;167:787-797.
FULL TEXT
Adaptive Immunity to Nontypeable Haemophilus influenzae
King et al.
Am. J. Respir. Crit. Care Med. 2003;167:587-592.
ABSTRACT
| FULL TEXT
Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease
Fabbri et al.
Am. J. Respir. Crit. Care Med. 2003;167:418-424.
ABSTRACT
| FULL TEXT
|
